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Abstract: This study aimed to elucidate the mechanisms explaining the persistence of anemia and
resistance to recombinant human erythropoietin (rHuEPO) therapy in a rat model of chronic kidney
disease (CKD)-associated anemia with formation of anti-rHuEPO antibodies. The remnant kidney
rat model of CKD induced by 5/6 nephrectomy was used to test a long-term (nine weeks) high
dose of rHuEPO (200 UI/kg bw/week) treatment. Hematological and biochemical parameters
were evaluated as well as serum and tissue (kidney, liver and/or duodenum) protein and/or
gene expression of mediators of erythropoiesis, iron metabolism and tissue hypoxia, inflammation,
and fibrosis. Long-term treatment with a high rHuEPO dose is associated with development of
resistance to therapy as a result of antibodies formation. In this condition, serum EPO levels
are not deficient and iron availability is recovered by increased duodenal absorption. However,
erythropoiesis is not stimulated, and the resistance to endogenous EPO effect and to rHuEPO
therapy results from the development of a hypoxic, inflammatory and fibrotic milieu in the
kidney tissue. This study provides new insights that could be important to ameliorate the current
therapeutic strategies used to treat patients with CKD-associated anemia, in particular those that
become resistant to rHuEPO therapy.
Keywords: chronic kidney disease; anemia; resistance to rHuEPO therapy; erythropoiesis; iron
metabolism; kidney hypoxia; inflammation and fibrosis; remnant kidney rat model
1. Introduction
Chronic kidney disease (CKD) is a debilitating disease affecting about 7% of people over the
age of 30, which translates to more than 70 million people in developed countries worldwide [1].
The increased prevalence of diabetes, hypertension and obesity, as well as the aging of the population,
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decisively contribute to perpetuate the rise of CKD [2,3]. Several studies have documented that
patients with CKD are at higher risk of cardiovascular diseases than the general population, and
show a higher rate of cardiovascular mortality, particularly end-stage renal disease (ESRD) patients,
who have a 500-fold greater risk than age-matched controls with normal renal function [4–7].
Anemia, a very common major complication of CKD, is already observed in early stages of
CKD (stage 2) and its prevalence and severity increases as renal failure progresses to more advanced
stages [8]. The most well-known cause of CKD anemia is an inadequate erythropoietin (EPO)
production; however, several events associated with the disease, including chronic inflammation,
blood loss, vitamin deficiencies, decreased iron absorption and utilization, might contribute also to
the anemia of CKD [8,9]. Recombinant human erythropoietin (rHuEPO) therapy has been used to
correct CKD associated-anemia, particularly in ESRD patients, improving their quality of life [9–14].
However, the impact on morbidity and mortality remains debatable, mainly due to the potential for
increase in adverse cardiovascular effects, namely increased risk of stroke, venous thromboembolism
and mortality [15–17]. There is a marked variability in the sensitivity to rHuEPO, with up to
10-fold changeability in dose requirements to achieve correction of the anemia, and 5%–10% of CKD
patients show weak responses [18]; this hyporesponsiveness (or resistance) to rHuEPO therapy is
associated with higher morbidity and mortality in ESRD patients [19,20]. Although the mechanisms
underlying this variability in response are unclear [21,22], resistance to rHuEPO therapy has been
associated with inflammation, oxidative stress and iron deficiency, as major causes, and with blood
loss, hyperparathyroidism, aluminum toxicity and vitamin B12 or folate deficiencies, as minor
causes [21–24]. In addition, a serious adverse effect of the long-term rHuEPO treatment is pure red
cell aplasia (PRCA). Although rHuEPO is weakly immunogenic, it may induce the production of
immunoglobulin (Ig) G antibodies against the recombinant molecules and the residual endogenous
EPO [25–27]. This adverse effect might become more common with the introduction of biosimilar
products, but the mechanisms underlying this form of resistance and the impact on the typical
features of this anemia remains to be elucidated.
Recent evidences suggest that CKD anemia might be due to a defective hypoxic signaling
rather than an inability of the EPO-producing cells to synthesize EPO [28,29]. A disturbance in iron
homeostasis is also a hallmark of the anemia of CKD, which usually presents as a functional iron
deficient anemia, with low serum iron and transferrin alongside with normal or even high ferritin [30]
explained by the underlying inflammatory process in CKD patients, presenting increased hepcidin
levels [31]. Hepcidin controls enterocyte iron absorption and macrophage iron mobilization by
linking to the iron exporter ferroportin present on the surface of those iron-releasing cells, triggering
its degradation [31]. In a previous study, we were able to describe iron metabolism, kidney hypoxia,
inflammation and fibrosis features in a rat model of CKD-associated anemia [29].
In addition, we have recently showed that a long-term (nine weeks) treatment of rats with
a high dose of rHuEPO (200 IU/kg bw/week) leads to anti-rHuEPO antibodies formation [32].
In this rat model of antibody-mediated erythroid hypoplasia without CKD, we found several changes
in erythropoiesis and iron metabolism. The anti-rHuEPO antibodies inhibited both endogenous
and recombinant EPO, leading to the development of anemia. This anemia leads to a serum iron
increase, stimulating hepcidin expression, despite no evidence of inflammation; thus, iron seems to
be the key modulator of hepcidin synthesis under these circumstances. The aim of this study is to
clarify the mechanisms underlying this hyporesponse to endogenous EPO, as well as the impact of
the long-term treatment of anemia with high doses of rHuEPO associated with antibody mediated
erythroid hypoplasia, in a rat model of CKD induced by 5/6 nephrectomy previously characterized
by us [29], focusing on iron metabolism, kidney hypoxia, inflammation and fibrosis.
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2. Results
2.1. Body and Tissue Weights and Blood Pressure
The CRF rats presented significantly reduced (p < 0.05) BW and higher (p < 0.01) KW/BW and
HW/BW ratios, when compared with Sham group, although KW and HW were similar (Table 1).
The CRF rats treated with 200 IU rHuEPO exhibited values similar to those found for CRF animals,
excepting a significantly lower (p < 0.05) KW/BW.
Table 1. Body and tissue weights, blood pressure and heart rate, hematological and biochemical data,
at the end of protocol.
Parameters Sham CRF CRF + 200 IU rHuEPO
Body and tissues weights
BW (kg) 0.45 ˘ 0.02 0.36 ˘ 0.01 a,1 0.39 ˘ 0.01
KW (g) 1.22 ˘ 0.03 1.65 ˘ 0.04 1.69 ˘ 0.08 a
KW/BW (g/kg) 2.72 ˘ 0.05 4.61 ˘ 0.22 aa 4.34 ˘ 0.20 aa,b
HW (g) 1.16 ˘ 0.03 1.24 ˘ 0.07 1.25 ˘ 0.04
HW/BW (g/kg) 2.58 ˘ 0.08 3.48 ˘ 0.25 aa 3.21 ˘ 0.14 a
LW (g/kg) 13.33 ˘ 0.48 11.32 ˘ 0.34 13.44 ˘ 0.42
LW/BW (g/kg) 29.61 ˘ 0.65 31.43 ˘ 0.71 34.41 ˘ 1.14 a
Blood pressure and heart rate
SBP (mmHg) 117.7 ˘ 1.15 134.1 ˘ 4.6 aa 169.1 ˘ 1.5 aaa,bbb
DBP (mmHg) 110.1 ˘ 0.59 113.2 ˘ 2.08 133.3 ˘ 7.2 aaa,bb
MBP (mmHg) 115.0 ˘ 0.97 117.5 ˘ 1.21 143.9 ˘ 4.8 aaa,bbb
HR (beats/min) 357.7 ˘ 2.74 367.6 ˘ 5.19 376.4 ˘ 3.2
Hematological data
WBC (ˆ103/µL) 1.78 ˘ 0.30 5.01 ˘ 1.76 3.16 ˘ 0.70
MCV (fL) 52.52 ˘ 0.53 51.93 ˘ 0.69 52.83 ˘ 0.81
MCH (pg) 18.08 ˘ 0.18 18.36 ˘ 0.24 18.60 ˘ 0.19
MCHC (g/dL) 34.60 ˘ 0.08 35.37 ˘ 0.19 aa 35.26 ˘ 0.30
RDW (%) 11.48 ˘ 2.53 18.34 ˘ 3.23 17.88 ˘ 0.67 a,b
PLT (ˆ103/µL) 713.75 ˘ 15.19 769.00 ˘ 73.17 786.00 ˘ 50.83
PDW (%) 16.34 ˘ 0.18 16.44 ˘ 0.20 16.44 ˘ 0.24
Biochemical parameters
TGs (mmol/L) 1.05 ˘ 0.14 1.58 ˘ 0.32 1.58 ˘ 0.29
Total-c (mmol/L) 1.25 ˘ 0.06 2.44 ˘ 0.54 a 2.74 ˘ 0.25
CK (U/L) 540.57 ˘ 58.94 473.00 ˘ 85.57 294.86 ˘ 35.86 a,b
ALT (U/L) 35.17 ˘ 2.21 42.00 ˘ 18.53 a 26.14 ˘ 1.18 a
AST (U/L) 80.57 ˘ 7.84 139.43 ˘ 70.70 54.57 ˘ 3.02 a,b
Bilirubin (µmol/L) 8.04 ˆ 10´5 ˘ 1.03 ˆ 10´5 1.03 ˆ 10´5 ˘ 1.71 ˆ 10´5 1.20 ˆ 10´5 ˘ 1.71 ˆ 10´5
IL-6 (pg/mL) 132.29 ˘ 4.28 138.33 ˘ 4.22 138.73 ˘ 1.70
hsCRP (µg/mL) 262.25 ˘ 12.43 225.31 ˘ 7.95 a 244.23 ˘ 7.99
INF-γ (pg/mL) 23.30 ˘ 3.10 25.51 ˘ 2.26 25.51 ˘ 1.22
TGF-β1 (ng/mL) 75.74 ˘ 5.62 84.13 ˘ 3.85 72.37 ˘ 4.55
VEGF (pg/mL) 4.23 ˘ 0.94 14.16 ˘ 2.24 a 10.03 ˘ 1.00 a
1 Results are presented as mean ˘ SEM (7 rats per group): a: p < 0.05, aa: p < 0.01, and aaa: p < 0.001 vs. Sham;
b: p < 0.05, bb: p < 0.01, and bbb: p < 0.001 vs. CRF. ALT: alanine transaminase; AST: aspartate transaminase;
BW: body weight; CK: creatine kinase; DBP: diastolic blood pressure; hsCRP: high-sensitive C reactive protein;
HR: heart rate; HW: heart weight; KW: kidney weight; LW: liver weight; MBP: mean blood pressure; MCH:
mean corpuscular hemoglobin; MCHC: mean cell hemoglobin concentration; MCV: mean corpuscular volume;
PDW: platelet distribution width; PLT: platelets; RDW: RBC distribution width; SBP: systolic blood pressure;
Total-c: serum total cholesterol; TGs: triglycerides; WBC: white blood cells.
The CRF rats presented significantly increased (p < 0.01) SBP and similar DBP, MBP and HR,
when compared with the normotensive Sham rats. The CRF rats treated with 200 IU rHuEPO,
presented significantly higher values of SBP (p < 0.001), DBP (p < 0.01) and MBP (p < 0.001) when
compared with CRF rats (Table 1).
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2.2. Hematological and Biochemical Data
The hematological and biochemical data for the different groups are presented in Figure 1 and
Table 1. The Sham rats showed normal sustained hematologic values throughout the entire study
(Figure 1A–D). Three weeks after the 5/6 nephrectomy, the CRF rats developed anemia, as shown
by the reduced Hb concentration, RBC count and HTC (p < 0.001 for all), when compared to Sham
group; RET count presented also a decrease (p < 0.05); this anemia persisted until the end of the
protocol. In the CRF rats treated with 200 IU rHuEPO therapy, the anemia was corrected and the rats
presented significantly increased Hb concentration, HTC, RBC and RET counts, when compared to
CRF rats. This erythropoietic response remained until the 9th week, after which the values returned
to basal levels (Figure 1A,D).
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excepting for a reduced (p < 0.05) RDW in Sham rats (Table 1). 
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time (p < 0.001 and p < 0.05, respectively), when compared with Sham group. Similar values of serum 
creatinine and BUN were observed between CRF rats treated with rHuEPO and those without 
treatment, throughout the entire protocol. Regarding the other biochemical data, the CRF rats 
presented increased (p < 0.05) total-cholesterol, ALT and VEGF, when compared with Sham rats 
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concentration (A); red blood cell count (B); hematocrit (C); reticulocyte count (D); creatinine (E);
and BUN concentrations (F). Results are presented as mean ˘ SEM (seven rats per group): a: p < 0.05
nd aaa: p < 0.001 vs. Sham; b: p < 0.05 and and bbb: p < 0.001 vs. CRF.
Concerning the other hematological measures, similar values (WBC, MCV, MCH, PLT and PDW)
were found between CRF and Sham group, excepting an increased (p < 0.01) MCHC in the CRF rats.
No significant differences were found between CRF, Sham and rHuEPO-treated rats, excepting for
a reduced (p < 0.05) RDW in Sham rats (Table 1).
In CRF rats, significantly (p < 0.001) increased serum creatinine and BUN concentrations
were found three weeks after 5/6 nephrectomy, as compared to Sham (Figure 1E,F, respectively).
These values remained high until the ninth week, after which a further increase was observed at the
final time (p < 0.001 and p < 0.05, respectively), when compared with Sham group. Similar values of
serum creatinine and BUN were observed between CRF rats treated with rHuEPO and those without
treatment, throughout the entire protocol. Regarding the other biochemical data, the CRF rats
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presented increased (p < 0.05) total-cholesterol, ALT and VEGF, when compared with Sham rats
(Table 1). All the analyzed parameters were similar between untreated and rHuEPO treated CRF
rats, excepting for a reduced AST in the group under 200 IU rHuEPO treatment.
Serum samples from all animals were also analyzed for anti-rHuEPO antibodies.
These antibodies were detected in seven out of seven (100%) CRF rats treated with 200 IU
rHuEPO, presenting a title of 1:2, while in all the Sham and CRF rats the anti-rHuEPO antibodies
were undetected.
2.3. Serum EPO Concentration and EPO and EPOR mRNA Expression in the Liver and Kidney
Both CRF untreated and rHuEPO-treated rats showed significantly higher (p < 0.001) serum
endogenous EPO concentrations, when compared with Sham group (Figure 2A). There was a notable
(p < 0.05) overexpression of EPO and EPO receptor (EPOR) mRNA in the kidney tissue of CRF rats,
when compared with Sham rats, an effect that was abolished in the presence of rHuEPO treatment
(Figure 2A,B). In the liver tissue, a significant overexpression (p < 0.001) of EPO mRNA was found
in CRF rats, when compared with Sham, which was not observed in rats under rHuEPO treatment.
EPOR mRNA levels were similar for all groups, excepting for a significant (p < 0.001) overexpression
in CRF rats treated with 200 IU rHuEPO (Figure 2A,B).
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The CRF rats, as compared to Sham, showed a significant (p < 0.001) decrease in serum iron and 
transferrin, and similar ferritin levels. The 200 IU rHuEPO-treated CRF rats presented iron, 
transferrin and ferritin serum levels similar to those of Sham rats; when compared to CRF rats, a 
significant (p < 0.05) increase in serum iron and no changes in ferritin and transferrin serum levels 
were found (Figure 3A). In the duodenum, no significant differences were observed for SLC40A1 and 
DMT1 mRNA expression between CRF and Sham rats. However, in the CRF + 200 IU rHuEPO group, 
there was a significant (p < 0.001) overexpression of DMT1 and a trend (p = 0.074) to increased 
expression of SLC40A1, when compared with the CRF group (Figure 3B). 
Figure 2. Erythropoietin (EPO) and erythropoietin receptor (EPOR): EPO in serum and kidney
and liver mRNA levels (A); and EPOR kidney and liver mRNA levels (B), at the end of the study
(12 weeks). Results are presented as mean ˘ SEM (seven rats per group): a: p < 0.05; aa: p < 0.01;
and aaa: p < 0.001 vs. Sham; bb: p < 0.01; and bbb: p < 0.001 vs. CRF.
2.4. Iron Metabolism
The CRF rats, as compared to Sham, showed a significant (p < 0.001) decrease in serum iron
and transferrin, and similar ferritin levels. The 200 IU rHuEPO-treated CRF rats presented iron,
transferrin and ferritin serum levels similar to those of Sham rats; when compared to CRF rats,
a significant (p < 0.05) increase in serum iron and no changes in ferritin and transferrin serum levels
were found (Figure 3A). In the duodenum, no significant differences were observed for SLC40A1
and DMT1 mRNA expression between CRF and Sham rats. However, in the CRF + 200 IU rHuEPO
group, there was a significant (p < 0.001) overexpression of DMT1 and a trend (p = 0.074) to increased
expression of SLC40A1, when compared with the CRF group (Figure 3B).
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Figure 3. Iron metabolism: Serum iron, ferritin and transferrin at final time (A); Relative gene
expression mRNA levels/18S of DMT1 and SLC40A1 in the duodenum (B); and of iron regulatory
proteins in the liver (C) at the end of protocol (12 weeks). Results are presented as mean ˘ SEM (7 rats
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Ferroportin (SLC40A1), hemojuvelin (HJV), soluble transferrin receptor (STFR), hemochromatosis
(Hfe), divalent metal transporter 1 (DMT1), transferrin receptor 1 (TfR1), m tri tase-2 (TMPRSS6),
interleuk -6 (IL-6) and bone morphogenic protein 6 (BMP6).
In the liver tissue, no significant alterations were found for mRNA expression of several iron
regulatory proteins (sTfR1, sTfR2, Hfe, HJV, BMP6, TMPRSS6, IL-6 and HIF-2α) in the CRF group
when compared with the Sham one (Figure 3C). However, there was a significantly reduced (p < 0.05)
expression of Hamp mRNA in the CRF rats, when compared with Sham animals (Figure 4A).
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The CRF rats under 200 IU rHuEPO therapy, as compared with the CRF ones, showed significant
changes in the liver expression of most of those mediators of iron metabolism, namely a significant
(p < 0.001) overexpression of sTfR1, sTfR2, Hfe, HJV, BMP6 and IL-6, and a significantly reduced
expression of TMPRSS6, Hamp and HIF-2α mRNA in the liver presented similar values vs. CRF
rats (Figures 3C and 4A,B, respectively). In addition, no significant differences were observed
between groups for hepcidin and HIF-2α protein expression (immunostaining) in the liver tissue
(Figure 4A,B, respectively).
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Figure 4. Liver hepcidin (A); and HIF2α (B) expression of mRNA and protein (immunohistochemical
staining). Original magnification ˆ400. Results are presented as mean ˘ SEM (seven rats per group):
a: p < 0.05; and aa: p < 0.01 vs. Sham.
2.5. Kidney Lesions
No significant changes were found in kidney histomorphology of Sham rats after the
experimental period (Tables 2 and 3; Figure 5). However, CRF rats presented several glomerular
and tubulointerstitial lesions. Concerning mild glomerular lesions, most of the CRF rats presented
thickening of Bowman’s capsule, hyalinosis of vascular pole, glomerular atrophy and hypercellularity
(Table 2; Figure 5A). In addition, all CRF rats presented at least one of the advanced glomerular
lesions, and mesangial expansion was present in five out of seven rats (Table 2; Figure 5A). The CRF
+ 200 IU rHuEPO rats, as compared to CRF ones, displayed an improvement in mild glomerular
lesions (Figure 5A3); however, the advanced lesions were still with a predominance of global
glomerulosclesosis (five out of seven rats) (Table 2; Figure 5A6). The changes reported are viewed
as the total scores of mild and advanced glomerular lesions (Table 2 and Figure 5A3,6).
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Table 2. Scoring and distribution (%) of mild and advanced glomerular kidneys lesions.
Mild Lesions Group Score (n, %)
0 (Absent) 1 (<25%) 2 (25%–50%) 3 (>50%) Total Score
Thickening of
Bowman´s
Capsule
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 1 (14.3%) 3 (42.9%) 1 (14.3%) 2 (28.6%) 1.57 ˘ 0.43 a,1
CRF + 200
IU rHuEPO 3 (42.9%) 3 (42.9%) 1 (14.3%) 0 0.71 ˘ 0.28
Hyalinosis of the
Vascular Pole
Sham 7 (100%) 0 0 (0%) 0 (0%) 0.00 ˘ 0.00
CRF 1 (14.3%) 6 (85.7%) 0 0 0.86 ˘ 0.14
CRF + 200
IU rHuEPO 5 (71.4%) 1 (14.3%) 0 1 (14.3%) 0.57 ˘ 0.43
Glomerular
Atrophy
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 1 (14.3%) 6 (85.7%) 0 0 0.86 ˘ 0.14 a
CRF + 200
IU rHuEPO 5 (71.4%) 2 (28.6%) 0 0 0.29 ˘ 0.18
Hypercellularity
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 0 7 (100%) 0 0 1.00 ˘ 0.00 aa
CRF + 200
IU rHuEPO 7 (100%) 0 0 0 0.00 ˘ 0.00 bb
Dilatation of the
Bowman’s Space
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 5 (71.4%) 2 (28.6%) 0 0 0.29 ˘ 0.18
CRF + 200
IU rHuEPO 5 (71.4%) 2 (28.6%) 0 0 0.28 ˘ 0.18
Total Group Score
Sham 0.00 ˘ 0.00
CRF 0.91 ˘ 0.12 aaa
CRF + 200
IU rHuEPO 0.37 ˘ 0.12 b
Group
Advanced Glomerular Lesions (n, %)
None of the
Previous
Lesions (0)
Thickening
of GBM (1)
Mesangial
Expansion
(2)
Nodular
Sclerosis (3)
Global
Glomerulosclerosis
(4)
Total Group
Score
Sham 7 (100%) 0 0 0 0 0.00 ˘ 0.00
CRF 0 1 (14.3%) 5 (71.4%) 1 (14.3%) 0 2.00 ˘ 0.22 aaa
CRF + 200 IU
rHuEPO 0 0 2 (28.6%) 0 5 (71.4%) 3.43 ˘ 0.37 aaa,bbb
1 Results are presented as mean ˘ SEM (seven rats per group): a: p < 0.05, aa: p < 0.01, and aaa: p < 0.001
vs. Sham; b: p < 0.05, bb: p < 0.01, and bbb: p < 0.001 vs. CRF.
Table 3. Scoring and distribution (%) of mild and advanced tubulointerstitial kidney lesions.
Mild Lesions Group Score (n, %)
0 (Absent) 1 (<25%) 2 (25%–50%) 3 (>50%) Total Score
Tubular
Hyaline
Droplets
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 0 7 (100%) 0 0 1.00 ˘ 0.00 aaa
CRF + 200
IU rHuEPO 0 7 (100%) 0 0 1.00 ˘ 0.00
aaa
TBM
Irregularity
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 0 3 (42.9%) 2 (28.5%) 2 (28.5%) 1.86 ˘ 0.34 aaa
CRF + 200
IU rHuEPO 0 5 (71.4%) 2 (28.5%) 0 1.29 ˘ 0.18
a
Tubular
Dilatation
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 2 (28.5%) 1 (14.3%) 2 (28.5%) 2 (28.5%) 1.57 ˘ 0.48 a
CRF + 200
IU rHuEPO 7 (100%) 0 0 0 0.00 ˘ 0.00 bb
Interstitial
Inflammatory
Infiltrate
Sham 4 (57.2%) 3 (42.9%) 0 0 0.29 ˘ 0.18
CRF 0 0 7 (100%) 0 2.00 ˘ 0.00 aaa
CRF + 200
IU rHuEPO 0 0 7 (100%) 2.00 ˘ 0.00
aaa
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Mild Lesions Group Score (n, %)
0 (Absent) 1 (<25%) 2 (25%–50%) 3 (>50%) Total Score
Vacuolar
Tubular
Degeneration
Sham 0 7 (100%) 0 0 1.00 ˘ 0.00
CRF 3 (42.9%) 3 (42.9%) 1 (14.3%) 0 0.71 ˘ 0.29 aaa
CRF + 200
IU rHuEPO 0 7 (100%) 0 0 1.00 ˘ 0.00 bb
Total Group
Score
Sham 0.26 ˘ 0.08
CRF 1.43 ˘ 0.15 aaa
CRF + 200
IU rHuEPO 1.06 ˘ 0.12
aaa
Advanced
Lesions
Group Score (n, %)
0 (Absent) 1 (<25%) 2 (25%–50%) 3 (>50%) Total Score
Hyaline
Cylinders
Sham 6 (85.7%) 1 (14.3%) 0 0 0.14 ˘ 0.14
CRF 0 1 (14.3%) 6 (85.7%) 0 1.86 ˘ 0.14 aa
CRF + 200
IU rHuEPO 0 0 4 (57.1%) 3 (42.9%) 2.43 ˘ 0.20
aaa
Tubular
Calcification
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF + 200
IU rHuEPO 1 (14.3%) 6 (85.7%) 0 0 0.85 ˘ 0.14 aaa,bbb
Necrosis
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 2 (28.6%) 5 (71.4%) 0 0 0.71 ˘ 0.18
CRF + 200
IU rHuEPO 0 0 4 (57.1%) 3 (42.9%) 2.43˘0.20 aaa,bbb
IFTA
Sham 7 (100%) 0 0 0 0.00 ˘ 0.00
CRF 0 3 (42.9%) 4 (57.1%) 0 1.57 ˘ 0.20 aaa
CRF + 200
IU rHuEPO 0 0 0 7 (100%) 3.00 ˘ 0.00 aaa,bbb
Total Group
Score
Sham 0.04 ˘ 0.04
CRF 1.04 ˘ 0.16 aaa
CRF + 200
IU rHuEPO 2.18 ˘ 0.17 aaa,bbb
1 Results are presented as mean ˘ SEM (seven rats per group): a: p < 0.05, aa: p < 0.01, and aaa: p < 0.001
vs. Sham; bb: p < 0.01, and bbb: p < 0.001 vs. CRF.
Concerning the mild tubulointerstitial lesions, all animals of the CRF group presented tubular
hyaline droplets, TBM irregularity, interstitial inflammatory infiltration, and most of them presented
tubular dilatation, as compared to Sham rats (Table 3 and Figure 5B). The group of CRF rats treated
with rHuEPO, as compared to CRF rats without treatment, showed a trend (p = 0.069) towards
a reduction in mild tubulointerstitial lesions (Table 3 and Figure 5B3), but a significant increase
in advanced lesions, namely in hyaline cylinders, calcification, necrosis and IFTA (Table 3 and
Figure 5B6).
As the changes in serum iron presented by CRF rats and CRF rats treated with rHuEPO could
be due to iron leakage due to kidney lesions, we performed iron staining according to Perls method.
We found that iron deposits were almost undetectable in Sham rats, increased in CRF rats (present in
six out of seven animals) and were prevented in the CRF + 200 IU rHuEPO rats (data not shown).
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Figure 5. Kidney histopathology. Representative glomerular and tubulointerstitial lesions observed 
in kidneys of rat groups under study, at the final time (PAS staining, original magnification × 400). 
(A1) glomerular hypercellularity; (A2) dilatation of the Bowman’s space and glomerular atrophy; (A3) 
total score of mild glomerular lesions for each rat group; (A4) nodular sclerosis; (A5) global 
glomerulosclerosis; (A6) total score of advanced glomerular lesions for each rat group; (B1) interstitial 
inflammatory infiltration; (B2) tubular basements membrane irregularity; (B3) total score of mild 
tubulointerstitial lesions in lesions for each rat group; (B4) Interstitial fibrosis and tubular atrophy 
(IFTA); (B5) tubular calcification; and (B6) total score of advanced tubulointerstitial lesions for each 
rat group. Results are presented as mean ± SEM (seven rats per group): aaa: p < 0.001 vs. Sham; b: p < 
0.05, and bbb: p < 0.001 vs. CRF. 
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We found that iron deposits were almost undetectable in Sham rats, increased in CRF rats (present 
in six out of seven animals) and were prevented in the CRF + 200 IU rHuEPO rats (data not shown). 
2.6. Mediators of Kidney Lesions 
No significant change was observed in kidney mRNA expression of TSP-1, Pro(III) collagen and 
CTGF in CRF rats, when compared with Sham, however a down-regulation of CytC and NF-κB 
expression (p < 0.05 and p < 0.01, respectively) was observed (Figures 6A,B). Major changes in kidney 
mRNA expression was observed in the CRF + 200 IU rHuEPO rats versus CRF animals; in fact, a 
significant overexpression of IL-1β, TSP-1, CytC, NF-κB and CTGF were found (Figure 6). Increased 
protein (immunostaining) expression of NF-κB and CTGF was encountered in the rHuEPO-treated 
CRF rats when compared with those untreated (Figures 6B,C, respectively). 
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Figure 5. Kidney histopathology. Representative glomerular and tubulointerstitial lesions observed
in kidneys of rat groups under study, at the final time (PAS staining, original magnification ˆ400).
(A1) glomerular hypercellularity; (A2) dilatation of the Bowman’s space and glomerular atrophy;
(A3) total score of mild glomerular lesions for each rat group; (A4) nodular sclerosis; (A5) global
glomerulosclerosis; (A6) total score of advanced glomerular lesions for each rat group; (B1) interstitial
inflammatory infiltration; (B2) tubular basements membrane irregularity; (B3) total score of mild
tubulointerstitial lesions in lesions for each rat group; (B4) Interstitial fibrosis and tubular atrophy
(IFTA); (B5) tubular calcification; and (B6) total score of advanced tubulointerstitial lesions for each
rat group. Results are presented as mean ˘ SEM (seven rats per group): aaa: p < 0.001 vs. Sham;
b: p < 0.05, and bbb: p < 0.001 vs. CRF.
2.6. Mediators of Kidney Lesions
No significant change was observed in kidney mRNA expression of TSP-1, Pro(III) collagen and
CTGF in CRF rats, when compared with Sham, however a down-regulation of CytC and NF-κB
expression (p < 0.05 and p < 0.01, respectively) was observed (Figure 6A,B). Major changes in
kidney mRNA expression was observed in the CRF + 200 IU rHuEPO rats versus CRF animals;
in fact, a significant overexpression of IL-1β, TSP-1, CytC, NF-κB and CTGF were found (Figure 6).
Increased protein (immunostaining) expression of NF-κB and CTGF was encountered in the
rHuEPO-treated CRF rats when compared with those untreated (Figure 6B,C, respectively).
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thrombospondin-1 (TSP-1), pro-(III) collagen, cytochrome c (Cyt C) and interleukin 1β (IL-1β) (A). 
Kidney expression of nuclear factor kappa B (NF-κB) gene and protein (immunohistochemical 
staining) (B) and connective tissue growth factor (CTGF) gene and protein (C). Original magnification 
× 400. Results are presented as mean ± SEM (seven rats per group): a: p < 0.05, aa: p < 0.01, and aaa: p 
< 0.001 vs. Sham; bb: p < 0.01, and bbb: p < 0.001 vs. CRF. 
2.7. Kidney mRNA and Protein Expression of Hypoxia Inducible Factor 2α and 2β 
No significant change was observed in kidney mRNA HIF-2α expression in the CRF rats, when 
compared to Sham animals, although a trend (p = 0.074) towards an increased protein expression 
(immunostaining) was found. The CRF + 200 IU rHuEPO rats presented an overexpression of both 
mRNA and protein in the kidney tissue (Figures 7A). In addition, increased mRNA and protein HIF-
2β expression was found in CRF + 200 IU rHuEPO rats, when compared with CRF rats (Figures 7B). 
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2.7. Kidney R and Protein Expression of Hypoxia Inducible Factor 2α and 2β
o significant change was observed in kidney mRNA HIF-2α expression in the CRF rats,
when compared to Sham animals, although a trend (p = 0.074) towards an increased protein
expression (immunostaining) was found. The CRF + 200 IU rHuEPO rats presented an
overexpression of both mRNA and protein in the kidney tissue (Figure 7A). In addition, increased
mRNA and protein HIF-2β expression was found in CRF + 200 IU rHuEPO rats, when compared
with CRF rats (Figure 7B).
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count, Hb concentration, HCT and reticulocytes, at the end of the protocol, these values were still 
similar to those presented by Sham rats; actually, as there were still normal values, CRF treated rats 
showed a kidney and liver EPO gene expression similar to that presented by Sham rats, in opposition 
to the anemic CRF rats presenting an overexpression. 
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vs. CRF.
3. Discussion
Animal models have been important tools to study the cellular and molecular changes in CKD,
and the remnant kidney model is one of the most used models [33–35]. Recently we characterized
erythropoiesis and iron metabolism in an animal model of erythroid hypoplasia induced by formation
of anti-rHuEPO antibodies in Wistar rats long-term treated with rHuEPO therapy [32]. The present
work aimed to study the mechanisms underlying the hyporesponse to endogenous EPO, as well as
the impact of long-term treatment of anemia with high rHuEPO doses leading to antibody mediated
erythroid hypoplasia, in a rat model of CKD induced by 5/6 nephrectomy previously characterized
by us [29]. The CRF rats present persistent anemia, without EPO deficiency, with low serum iron
and transferrin levels, although iron storage was normal, and unchanged serum IL-6 and hsCRP
levels, showing the absence of systemic inflammation. In addition, despite the reduced expression
of hepcidin that favors iron absorption, serum iron was reduced, which might be due to iron loss
through the damaged kidney. It was reported that in proteinuric conditions, due to glomerular
leakage of transferrin, iron might be released from transferrin in the acid milieu of the tubular
lumen [36], leading to iron accumulation in the proximal tubule [36–39] and worsening of CKD.
Another hypothesis for the persistence of the anemia in CRF rats is that an altered activity/function
of EPO has occurred, resulting from kidney cell damage, supported by previous reports [40,41].
We must also consider the hypothesis that the endogenous EPO concentration is inadequate to
overcome anemia.
The treatment of CRF rats with a high dose of rHuEPO (200 IU/kg bw/week) rapidly corrected
the anemia, and the Hb concentration reached significantly higher values until the ninth week,
as compared to Sham and CRF rats; afterwards, the hematological measures declined to basal values,
similar to those of the Sham group, due to formation of EPO-neutralizing antibodies. This condition
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has been reported in humans [42,43] and, more recently, has increased due to the introduction of EPO
biosimilars to treat anemia in some countries [26,27].
The serum EPO levels in CRF group were significantly increased, as compared to Sham rats,
and were similar to EPO levels presented by the CRF rats, though presenting a trend towards
increased values. This slight increase might be explained by a compensatory production of EPO
by the liver, given the significant overexpression of EPOR mRNA in hepatic tissue. While the liver
has a role in EPO production in the fetal age, in the adulthood the main producer of EPO is the
kidney [44–46]. However, in renal disease conditions the extra-renal tissues, such as the liver, might
assume a higher part on the compensatory synthesis of EPO. Despite the striking reduction in RBC
count, Hb concentration, HCT and reticulocytes, at the end of the protocol, these values were still
similar to those presented by Sham rats; actually, as there were still normal values, CRF treated rats
showed a kidney and liver EPO gene expression similar to that presented by Sham rats, in opposition
to the anemic CRF rats presenting an overexpression.
Renal failure was accompanied by a compensatory renal hypertrophy and angiogenesis in the
CRF rats, as revealed by the increase in KW/BW and serum VEGF levels; a high HW/BW ratio
was also found in the CRF group, which might be caused by the supplementary effort of the left
ventricle muscle to pump blood in this condition of anemia secondary to renal failure development
(Table 1). CKD patients usually present a concomitant rise in systolic blood pressure [47–50], which
was also observed in the CRF rats of our study, explaining the cardiac hypertrophy. When treated
with 200 IU rHuEPO, there was an aggravation of hypertension, which is a widely described rHuEPO
side-effect [47–50] that contributes to high morbidity and mortality of CKD patients [28,48].
Interestingly, rHuEPO therapy presented a dual impact on kidney lesions. In fact,
while an amelioration of mild glomerular and tubulointerstitial lesions was found, advanced lesions
were intensified (Tables 2 and 3 and Figure 5), suggesting the inability to protect the kidney in
advanced stages of CKD. Concomitantly, CRF rats treated with 200 IU rHuEPO also presented
significantly higher values in protein and/or gene expression of several mediators of kidney
inflammation and fibrosis, namely, Cyt C, IL-1β, and CTGF (Figure 6).
Under hypoxic conditions, HIFs promote the transcription of regenerative factors, such as
EPO, GLUT receptor, VEGF and CTGF, among others [51–53]. However, some of them (namely
VEGF and CTGF) might contribute to worsening of kidney disease by promoting inflammation
and fibrosis [53,54]. It is becoming widely accepted that, regardless of the initial cause of renal
failure, tubulointerstitial fibrosis is the major cause of disease progression [55,56]. Tubulointerstitial
damage is typically associated with accumulation of extracellular matrix, infiltration of inflammatory
cells, increased number of interstitial fibroblasts, tubular atrophy and finally loss of peritubular
capillaries [57]. Given the close association between hypoxia, EPO synthesis, fibrosis and
inflammation, it is of major importance to elucidate how rHuEPO therapy affects the evolution of
kidney lesions.
Despite the still normal Hb concentration, our data is consistent with a hypoxic environment
in the kidney of CRF rats treated with rHuEPO, as suggested by the increased expression of HIFs
(Figure 7) and by the increase in serum EPO, which is, however, unable to properly stimulate
erythropoiesis, due to the formation of EPO-neutralizing antibodies (Figure 8). This is, probably, due
to the sudden decrease in Hb concentration leading to a striking reduction in kidney oxygenation;
another hypothesis is that the high blood viscosity associated to high RBC concentration during about
3–6 weeks could induce stasis, triggering hypoxia in renal tissue. Hypoxia-induces the expression of
local inflammatory and fibrosis mediators, such as NF-κB and CTGF, contributing to aggravation of
kidney damage (Figure 8).
Iron metabolism impairment has been viewed as a major feature of CKD-associated anemia
and hepcidin (de)regulation is one of the key pieces for resistance to rHuEPO therapy [29,30,58–60].
Hepatic Hamp (hepcidin gene) expression is regulated by several proteins, namely Hfe, TfR1, TfR2,
HJV, BMP6, matriptase-2 and transferrin [61–63]. In the liver, diferric transferrin competes with
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TfR1 for binding to Hfe, and, when iron is increased, more Hfe is available to bind to TfR2; this
complex, TfR2-Hfe, promotes HJV binding to BMP6, increasing hepcidin synthesis [64,65]. Moreover,
hypoxia and EPO, as well as twisted gastrulation protein 1 (TWSG1), erythroferrone and growth
differentiation factor 15 (GDF15) [66], all produced by erythroblasts, are also important modulators
of hepcidin, downregulating its synthesis [66].
In the CRF rats, despite the increased EPO serum levels, anemia persisted and was linked to
low serum iron and transferrin levels, while serum IL-6 and hsCRP levels showed the absence of
systemic inflammation. The increased expression of duodenal ferroportin favours iron absorption;
however, as referred, serum iron is reduced, which might be due to iron leakage in kidney lesions, as
showed by tubular iron accumulation (data not shown). In the CRF rats under rHuEPO treatment,
iron was normal (similar to Sham rats) and was associated with an overexpression of Tf, TfR2,
BMP6, Hfe and HJV in the liver, and, in agreement, with an overexpression of Hamp; moreover,
downregulation of matriptase-2 mRNA expression was observed in the liver that might further
contribute to overexpression of hepcidin (Figures 3 and 4). However, this hepcidin overexpression
was not accompanied by higher protein expression, as showed by the immunochemical studies.
A similar profile was found for liver HIF-2α mRNA and protein expression. The normal serum
iron levels in the rats treated with rHuEPO, versus untreated, seems to be due to increased
iron absorption, as suggested by the duodenal overexpression of iron transporters (DMT1 and
ferroportin) (Figure 3). Nevertheless, increased iron availability is not accompanied by recovering
of erythropoiesis, which might be due to the formation of anti-EPO antibodies, as well as to the
kidney hypoxic, inflammatory and fibrotic milieu, which might be responsible for the impaired EPO
erythropoietic activity (Figure 8).
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This study has some limitations that future research will cover. One of the aspects for further
research is the comparison of our model of CRF-associated anemia induced by 5/6 nephrectomy
with other models of anemia, such as the bleeding model used by other groups [67]. This comparison
will be important to strength the data regarding the variations of serum EPO and hepcidin levels
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in the rat, which are strongly influenced by other players, including concentration of Hb, serum
iron and ferritin, as previously demonstrated [68,69]. In addition, measure of hepcidin protein
levels will be important to complete the information of gene expression. We also acknowledge the
interest of evaluating the bone marrow erythropoietic acitivity, by quantification of the myeloid:
erythroid ratio. Regarding cardiovascular influences or impact, a longitudinal study of blood
pressure data throughout the study time-points will potentially add interesting information to that
already observed.
4. Experimental Section
4.1. Animals and Experimental Protocol
Male Wistar rats (Charles River Lab., Inc., Barcelona, Spain) weighing 300 g were maintained
in an air conditioned room, subjected to 12 h dark/light cycles and given standard rat chow
(IPM-R20, Letica, Barcelona, Spain) ad libitum and free access to tap water. Animal experiments
were conducted according to the European Communities Council Directives on Animal Care.
The experiments were approved by the Portuguese Foundation for Science and Technology
(PTDC/SAU-TOX/114253/2009) and the Local Ethics Committee of the Faculty of Medicine from
the University of Coimbra (ORBEA — Organ Responsible for the Animal Welfare).
The rats were divided into three groups (7 rats each): Sham group—submitted to surgical
process but without kidney mass reduction and rHuEPO treatment; CRF group—induced by
a two-stage (5/6) nephrectomy (about 2/3 of the left kidney was removed by left flank incision
and, one week later, the right kidney was removed through identical procedure); and CRF + 200 IU
rHuEPO group—treated with rHuEPO (beta epoetin), 200 IU/kg/week s.c., Recormonr (Roche
Pharmaceuticals—Roche Farmacêutica Química, Lda., Amadora, Portugal) after the third week of
surgery. All animals completed the 12 weeks of protocol. Body weight (BW) was monitored
throughout the study and blood pressure (BP) and heart rate (HR) measures were obtained using
a tail-cuff sphygmomanometer LE 5001 (Letica, Barcelona, Spain), using the conditions of rat
acclimatization and collection of data previously described by us [70].
4.2. Sample Collection and Preparation
At the beginning of the experiments (T0) and at 3 (T1), 6 (T2), 9 (T3) and 12 (T4) weeks
after the surgical (5/6) nephrectomy, the rats were subjected to intraperitoneal anesthesia with
a 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalarr, Parke-Davis, Lab. Pfeizer Lda, Seixal,
Portugal) solution in 2.5% chlorpromazine (Largactilr, Rhône-Poulenc Rorer, Lab. Vitória, Amadora,
Portugal). Blood samples were collected by venipuncuture, from the jugular vein, into vacutainer
tubes without anticoagulant (to obtain serum) or with K3EDTA for hematological and biochemical
studies; only 3 mL of blood were collected at T0, T1, T2 and T3, to minimize interference with
erythropoiesis mechanism and to monitor anemia and renal function; at the end of protocol (T4),
10 mL of blood were collected to perform all the biochemical and hematological assays.
At the end of the protocol, after collection of blood, the rats were sacrificed by cervical dislocation
and the kidneys, heart, liver and duodenum were removed, and placed in ice-cold Krebs–Henseleit
buffer. The body weight (BW); the weight of kidney (KW) or of the 1/6 remnant kidney; the heart
weight (HW); and the liver weight (LW) were measured to calculate the trophism indexes (KW/BW,
HW/BW and LW/BW).
4.3. Biochemical and Hematological Assays
The following serum markers were analyzed on a Hitachi 717 analyzer (Roche Diagnostics
Inc., Massachuasetts, MA, USA) using standard methods: creatinine, blood urea nitrogen (BUN),
as renal function markers; glycose, serum total cholesterol (Total-c), triglycerides (TGs), creatine
kinase (CK), aspartate transaminase (AST), and alanine transaminase (ALT). Quantification of total
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bilirubin was performed by a colorimetric test (diazotized sulfanilic acid reaction, Roche Diagnostics).
Serum levels of interleukin-6 (IL-6), interferon-γ (IFN-γ), transforming growth factor (TGF-β1) and
vascular endothelial growth factor (VEGF) were all measured by rat-specific Quantikine ELISA
kits from R&D Systems (Minneapolis, MN, USA). High-sensitive C-reactive protein (hsCRP) was
determined by using a rat-specific Elisa kit from Alpha Diagonostic International (San Antonio, TX,
USA). Serum levels of erythropoietin (EPO) were evaluated by rat specific ELISA kit (MyBioSource,
San Diego, CA, USA). All assays were performed according to the manufacturers’ recommendations.
Red blood cell (RBC) count, hematocrit (Hct), hemoglobin concentration (Hb), mean corpuscular
hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), mean corpuscular volume (MCV),
RBC distribution width (RDW), platelet distribution width (PDW), platelets (PLT) and white blood
cell (WBC) count were assessed in whole blood K3EDTA (Coulter Counterr, Beckman Coulter, Inc.,
Fullerton, CA, USA); reticulocyte (RET) count was performed by microscopic counting on blood
smears after vital staining with New methylene blue (Reticulocyte stain, Sigma–Aldrich, St. Louis,
MO, USA). Serum iron concentration was determined using a colorimetric method (Iron, Randox
Laboratories Ltd., North Ireland, UK), whereas serum ferritin and transferrin were measured by
immunoturbidimetry (Laboratories Ltd., North Ireland, UK).
4.4. Detection of Anti-EPO Antibodies
To detect anti-EPO antibodies we used an ELISA technique, according to Urra et al., using
rHuEPO (Recormonr, Roche Pharmaceuticals) as antigen and, as secondary antibody, goat anti-rat
IgG conjugated with horseradish peroxidase (Sigma; 100 ng/mL for 1 h, at room temperature) [71].
The substrate tetramethylbenzidine (TMB) (Sigma) was added and the reaction was stopped by
the addition of sulfuric acid 1.25 mol/L. The optical density at 450 nm (OD450) was determined
with an automatic plate reader.
4.5. Gene Expression Analysis
In order to isolate total RNA, 0.2 g samples of liver, duodenum and kidney, from each rat, were
immersed in RNA laterTM (Ambion, Austin, TX, USA) upon collection and stored at 4 ˝C for 24 h;
afterwards, samples were frozen at ´80 ˝C. Subsequently, tissue samples weighing 50 ˘ 10 mg were
homogenized in a total volume of 1 mL TRIr Reagent (Sigma, Sintra, Portugal) using a homogenizer,
and total RNA was isolated according to TRIr Reagent Kit recommendations. To ensure inactivation
of contaminating RNAses, all material used was cleaned and immersed in RNAse-free water (0.2%
diethyl pyrocarbonate) for 2 h and finally heated at 120 ˝C for 1 h. RNA integrity (RIN, RNA
Integrity Number) was analyzed using 6000 Nano ChipW kit, in Agilent 2100 bioanalyzer (Agilent
Technologies, Walbronn, Germany) and 2100 expert software, following manufacturer instructions.
The yield from isolation was from 0.5 to 1.5 µg; RIN values were 7.0–9.0 and purity (A260/A280)
was 1.8–2.0. The concentrations of the RNA preparations were confirmed with NanoDrop1000
(ThermoScientific, Wilmington, DE, USA). Possible contaminating remnants of genomic DNA were
eliminated by treating these preparations with deoxyribonuclease I (amplification grade) prior to
RT-qPCR amplification. Reverse transcription and relative quantification of gene expression were
performed as previously described [72]. Real-time qPCR reactions were performed using the primer
sequences listed in Table 4 for the genes analyzed. Results were analyzed with SDS 2.1 software
(Applied Biosystems, Foster City, CA, USA) and relative quantification calculated using the 2∆∆Ct
method [73]. In liver tissue we studied the EPO, EPOR, TfR1, TfR2, Hamp, Il-6, SLC40A1, HJV, TF,
Hfe, BMP6 and TMPRSS6 gene expression; in duodenum tissue the gene expression of DMT1 and
SLC40A1 were studied, and in the kidney we evaluated the expression of EPO, EPOR, IL-1β, TSP-1,
Pro (III) collagen, CytC, NF-kB, CTGF, VEGF, HIF-2α and HIF-2β genes.
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Table 4. List of primer sequences (F: forward; R: reverse).
Gene Primer Sequences Gene Primer Sequences
EPO
F: 5’-AGG GTC ACG AAG CCA TGA AG-3’
IL-6
F: 5’-CGA GCC CAC CAG GAA CGA AAG TC-3’
R: 5’-GAT TTC GGC TGT TGC CAG TG-3’ R: 5’-CTG GCT GGA AGT CTC TTG CGG AG-3’
EPOR
F: 5’-GCG ACT TGG ACC CTC TCA TC-3’ IL-1β F: 5’-CTC TGT GAC TCG TGG GAT GAT G-3’
R: 5’-AGT TAC CCT TGT GGG TGG TG-3’ R: 5’-CAC TTG TTG GCT TAT GTT CTG TCC-3’
Hamp F: 5’-GAA GGC AAG ATG GCA CTA AGC-3’ CTGF
F: 5’-CGT AGA CGG TAA AGC AAT GG-3’
R: 5’-CAG AGC CGT AGT CTG TCT CG-3’ R: 5’-AGT CAA AGA AGC AGC AAA CAC-3’
TfR2 F: 5’-CAA GCT TCG CCC AGA AGG TA-3’ NF-κβ F: 5’-ACC TGA GTC TTC TGG ACC GCT G-3’
R: 5’-CGT GTA AGG GTC CCC AGT TC-3’ R: 5’-CCA GCC TTC TCC CAA GAG TCG T-3’
SLC40A1
F: 5’-CAG GCT TAG GGT CTA CTG CG-3’
VEGF
F: 5’-GAA GTT CAT GGA CGT CTA CCA G -3’
R: 5’-CCG AAA GAC CCC AAA GGA CA-3’ R: 5’-CAT CTG CTA TGC TGC AGG AAG CT -3’
HJV F: 5’-GCC TAC TTC CAA TCC TGC GT-3’
Pro (III)
Collagen
F: 5’-CCA CCC TGA ACT CAA GAG TGG-3’
R: 5’-GGT CAA GAA GAC TCG GGC AT-3’ R: 5’-CCA TCC AGA ACT GTG TAA GTG-3’
TF
F: 5’-GGC ATC AGA CTC CAG CAT CA-3’
TSP-1
F: 5’-CCG GTT TGA TCA GAG TGG T-3’
R: 5’-GCA GGC CCA TAG GGA TGT T-3’ R: 5’ GGT TTC GGA AGG TGC AAT-3’
Hfe F: 5’-CTG GAT CAG CCT CTC ACT GC-3’ Cyt C F: 5’- CTT GTC ATA AAG TGG ATA TGA TC-3’
R: 5’-GTC ACC CAT GGT TCC TCC TG-3’ R: 5’ CAA TAG GTT TGA GGC GAC ACC CTC-3’
DMT1
F: 5’-CAA CTC TAC CCT GGC TGT GG-3’
HIF-2α
F: 5’-TGA CTT CAC TCA TCC TTG CGA CCA-3’
R: 5’-GTC ATG GTG GAG CTC TGT CC-3’ R: 5’-ATT CAT AGG CAG AGC GGC CAA GTA-3’
TfR1 F: 5’-GCT CGT GGA GAC TAC TTC CG-3’ HIF-2β F: 5’-TGA AAG AAG GAG AAG CCC AAT A-3’
R: 5’-GCC CCA GAA GAT GTG TCG G-3’ R: 5’-CAT CAG AGT TAT GCC GAG ACA G-3’
TMPRSS6
F: 5’-CCG AAT ATG AGG TGG ACC CG-3’
18S
F: 5’-CCA CTA AAG GGC ATC CTG GG-3’
R: 5’-GGT TCA CGT AGC TGT AGC GG-3’ R: 5’-CAT TGA GAG CAA TGC CAG CC-3’
BMP6
F: 5’-GCT GCC AAC TAT TGT GAC GG-3’
Actb
F: 5’-GAG ATT ACT GCC CTG GCT CC-3’
R: 5’-GGT TTG GGG ACG TAC TCG G-3’ R: 5’-CGG ACT CAT CGT ACT CCT GC-3’
4.6. Histopathological Analysis
Tissue samples were fixed in Bock’s fixative and embedded in paraffin wax; 4 µm thick sections
were stained for routine histopathological studies with haematoxylin and eosin (H&E). Periodic acid
of Shiff (PAS) was used to evaluate and confirm the levels of mesangial expansion, thickening of
basement membranes and sclerotic parameters. For PAS staining, the samples were fixed in neutral
formalin 10%, embedded in paraffin wax, and 4 µm thick sections were immersed in water and
subsequently treated with an aqueous solution of periodic acid (1%), then washed to remove any
traces of the periodic acid, and finally treated with Schiff’s reagent. All samples were examined by
light microscopy using a Microscope Zeiss Mod. Axioplan 2. The degree of injury visible by light
microscopy was scored by two pathologists, on a blind fashion. Lesions were evaluated on the total
tissue on the slide.
Glomerular and tubulointerstitial kidney lesions were classified as mild and advanced.
Mild glomerular damage was assessed by evaluating thickening of Bowman capsule, hyalinosis
of the vascular pole, glomerular atrophy, hypercellularity and dilatation of Bowman´s space.
Advanced glomerular damage was assessed by grading sequentially four main lesions, from least
to worst one: 1—thickening of glomerular basement membrane (GBM); 2—mesangial expansion;
3—nodular sclerosis; and 4—global glomerulosclerosis. When advanced lesions were presented at
a given glomerulli, the analysis of mild lesions become unavailable. Mild tubulointerstitial lesions
included tubular hyaline droplets, tubular basement membrane (TBM) irregularity, tubular dilatation,
interstitial inflammatory infiltration and vacuolar tubular degeneration. Advanced tubulointerstitial
lesions were assessed by the presence of hyaline cylinders, tubular calcification, necrosis and the
association of interstitial fibrosis and tubular atrophy (IFTA). The evaluation of vascular lesions was
focused on arteriolar hyalinosis, arteriolosclerosis and arteriosclerosis. A semiquantitative rating for
each slide, ranging from normal (or minimal) to severe (extensive damage), was assigned to each
component, according to previously described [29]. Perl’s staining of kidney slides was performed to
search for kidney iron accumulation.
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4.7. Immunohistochemistry Analysis
Liver and renal cortex/medulla paraffin sections (4 µm) were processed for
immunohistochemistry (IHC) analysis according to previously described [29]. The following
primary antibodies were used: from Abcam Inc. (Cambridge, UK) for detection of hepcidin
(dilution 1:150, ab81010) and CTGF (dilution 1:250, ab6992) and from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA) for detection of NF-κB p50 (dilution 1:500, sc-114), HIF-2α (dilution
1:250, sc-28706), and HIF-2β (dilution 1:100, sc-5581). For IHC quantification, five 400 ˆ microscopic
views of liver and renal cortex and medulla per slide were selected randomly and photographed
using a Leica DFC480 microscope (Leica Microsystems, Wetzlar, Germany). The area and intensity
of positive staining and the Quick Score calculation were performed according to previously
described [29,74]. IHC studies were evaluated independently by two pathologists blinded to the
data. Slight differences in interpretation were resolved by simultaneous viewing.
4.8. Statistical Analysis
For statistical analysis, we used the IBM SPSS Statistics 20 (2011). Significance level was accepted
at p less than 0.05. Results are presented as means ˘ standard error of means (SEM). Comparisons
between groups were performed using ANOVA and the post hoc Tukey test.
5. Conclusions
In the remnant kidney rat model of CKD-associated anemia, long-term treatment with a high
rHuEPO dose is associated with development of resistance to rHuEPO therapy as a result of anti-EPO
antibodies formation. In this condition, serum EPO levels are not deficient and iron availability is
improved by increased duodenal absorption. The resistance to endogeneous EPO and to rHuEPO
therapy seems to result from the development of a hypoxic, inflammatory and fibrotic milieu in the
kidney tissue. This study provides new insights that could be important to ameliorate the current
therapeutic strategies used to treat patients with CKD-associated anemia, in particular those that
become resistant to rHuEPO therapy. Prevention of evolution to end-stage renal disease and increase
therapy efficacy without aggravation of cardiovascular outcome is pivotal for patients suffering from
CKD, which incidence is alarmingly increasing worldwide.
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